What question did this study set out to answer?

To evaluate the immunogenicity, protective efficacy, and stability of an adeno-associated viral vector vaccine targeting the SARS-CoV-2 spike protein.

August 7, 2021Cell Host & MicrobeOpen Access

An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates

View Full Paper

Ask AI

Bookmark

Authors

NZNerea ZabaletaMassachusetts Eye and Ear Infirmary WDWenlong DaiNanjing Medical University UBUrja BhattUniversity of North Carolina at Chapel Hill

Discussion

Member takes

Implication

Preclinical study demonstrates complete protection against SARS-CoV-2 in non-human primates following a single injection, suggesting a scalable platform for global vaccination campaigns.

Key Points

To evaluate the immunogenicity, protective efficacy, and stability of an adeno-associated viral vector vaccine targeting the SARS-CoV-2 spike protein.
Administered a single intramuscular injection of the AAVCOVID-1 vaccine candidate to mice and non-human primates (macaques).
Assessed long-term neutralizing antibody persistence over one year, memory T cell activity, and room-temperature storage stability.
Challenged vaccinated macaques with SARS-CoV-2 to determine protective efficacy in vivo.
A single low-dose injection conferred complete protection against SARS-CoV-2 viral challenge in macaques.
Peak neutralizing antibody titers remained sustained at one year and were accompanied by functional memory T cell responses.
The vaccine maintained stability at room temperature for one month, while vector genome persistence and expression waned over time.

Cite This Study

Zabaleta et al. (2021) studied this question.

synapsesocial.com/papers/6a825a69d75a4241da93b3c2 https://doi.org/10.1016/j.chom.2021.08.002

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates complete protection against SARS-CoV-2 in non-human primates following a single injection, suggesting a scalable platform for global vaccination campaigns.

An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates

Discussion

Member takes

Implication

Key Points

Cite This Study

An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider